title: Rituximab for patients with myopathy associated with anti-signal recognition particle antibodies: comment on the article by Valiyil et al.
authors.forename: Christophe
authors.initials: C
authors.lastname: Deligny
authors.forename: Vincent
authors.initials: V
authors.lastname: Goëb
authors.forename: Maryvonne
authors.initials: M
authors.lastname: Dueymes
authors.forename: Valentine
authors.initials: V
authors.lastname: Kahn
authors.forename: Véronique
authors.initials: V
authors.lastname: Dehlinger
authors.forename: Georges Jean
authors.initials: GJ
authors.lastname: Baptiste
authors.forename: Khadija
authors.initials: K
authors.lastname: Amarof
authors.forename: Serge
authors.initials: S
authors.lastname: Arfi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D018908:Muscle Weakness / Q000276:immunology*; D009220:Myositis / Q000276:immunology*; D018271:Signal Recognition Particle / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D018271:Signal Recognition Particle